All In Biotech

Drug Trial Radar · NCT04925674

Study of HEC53856 in Patients With Subjects With End-Stage Renal Disease Receiving Dialysis.

Phase Ic Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HEC53856 Capsules in Subjects With Renal Anemia on Dialysis

Last checked: Nov 19, 2026Latest source record: May 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

Sep 10, 2021

Primary completion

Oct 19, 2022

Study completion Oct 19, 2022

Sponsor

Lead sponsor
Sunshine Lake Pharma Co., Ltd.Industry
Sponsor type
Industry
Collaborators
Nicoya Therapeutics (Shanghai) Co., Ltd.
First posted
Jun 14, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of HEC53856 capsules on anemia in subjects with chronic kidney disease on dialysis.

Conditions

  • Hemodialysis
  • Peritoneal Dialysis

Interventions

  • HEC53856Drug

    The 100mg dose cohort in the hemodialysis: D1 single oral administration of the investigation product 2.5h before hemodialysis; Three times a week for 6 weeks starting from D8, oral administration of the test drug 2.5h after hemodialysis. The rest dose cohorts in the hemodialysis: Three times a week for 6 weeks starting from D1, oral administration of the investigation product 2.5h after hemodialysis. The dose cohort in the peritoneal dialysis: Three times a week for 6 weeks starting from D1, oral administration of the investigation product after fasting.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse EventsTime frame: Up to 2 weeks after last dose

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Sichuan Provincial People's Hospital

    Chengdu, China

  • The First Affiliated Hospital of Shantou University Medical College

    Shantou, China

  • The First Hospital of China Medical University

    Shenyang, China

  • General Hospital of Tianjin Medical University

    Tianjin, China

  • Affiliated Hospital of Guangdong Medical University

    Zhanjiang, China

  • The Fifth Affiliated Hospital Sun Yat-sen University

    Zhuhai, China

  • The First Affiliated Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.